Overview

Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients With Granuloma Annulare

Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
Study AC-1101-GA-001 is an early phase open-label study with a 4-week treatment and 2-week follow-up period (without treatment) to assess the safety, tolerability, and efficacy of AC-1101 gel in patients with Granuloma Annulare.
Phase:
Phase 1
Details
Lead Sponsor:
TWi Biotechnology, Inc.
Treatments:
Tofacitinib